We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Concerns with CMO Draw CRL for Allergan’s Levadex
Concerns with CMO Draw CRL for Allergan’s Levadex
April 19, 2013
Allergan has received a complete response letter (CRL) for its aerosol-based migraine drug Levadex.